Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity

Colloids and Surfaces B: Biointerfaces

Volumn 111, Issue , 2013, Pages 755-763

  Mendes, A I ^a   Silva, A C ^b,c   Catita, J A M ^b,d   Cerqueira, F ^b,e   Gabriel, C ^b   Lopes, C M ^a,b  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d Paralab SA   (Portugal)

^e University of Porto   (Portugal)

Author keywords

Antifungal activity; Controlled release; Hydrogel; Miconazole; Nanostructured lipid carriers; Oral mucosa

Indexed keywords

ANTI-FUNGAL ACTIVITY; CONTROLLED RELEASE; MICONAZOLE; NANOSTRUCTURED LIPID CARRIERS; ORAL MUCOSA;

DISPERSIONS; DRUG DELIVERY; FUNGI; HYDROGELS;

ENCAPSULATION;

BENZALKONIUM CHLORIDE; DRUG CARRIER; EXCIPIENT; GELLING AGENT; GELUCIRE; GLYCEROL; LIPID; MICONAZOLE; MIGLYOL; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; POLYSORBATE 80; UNCLASSIFIED DRUG; WATER; ANTIFUNGAL AGENT; HYDROGEL; PLACEBO;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HYDROGEL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR STABILITY; MOUTH MUCOSA; NANOANALYSIS; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; CHEMISTRY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECTS; FLOW KINETICS; KINETICS; MEDICINAL CHEMISTRY; PHARMACOLOGY; STATIC ELECTRICITY;

ANTIFUNGAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CANDIDA ALBICANS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYDROGELS; KINETICS; LIPIDS; MICONAZOLE; MOUTH MUCOSA; NANOSTRUCTURES; PARTICLE SIZE; PLACEBOS; RHEOLOGY; STATIC ELECTRICITY;

EID: 84882791479     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.05.041     Document Type: Article

References (75)

1. Bensadoun R.J., Daoud J., El Gueddari B., Bastit L., Gourmet R., Rosikon A., Allavena C., Ceruse P., Calais G., Attali P. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008, 112:204-211.
2. Ellepola A.N., Samaranayake L.P. Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis. Dent. Update 2000, 27:164-172. 165-170.
3. Akpan A., Morgan R. Oral candidiasis. Postgrad. Med. J. 2002, 78:455-459.
4. Pemberton M.N., Oliver R.J., Theaker E.D. Miconazole oral gel and drug interactions. Brit. Dent. J. 2004, 196:529-531.
5. Ribeiro A.M., Figueiras A., Freire C., Santos D., Veiga F. Combining strategies to optimize a gel formulation containing miconazole: the influence of modified cyclodextrin on textural properties and drug release. Drug Dev. Ind. Pharm. 2010, 36:705-714.
6. Muller R.H. R. Shegokar and C.M. Keck, 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discovery Technol. 2011, 8:207-227.
7. Esposito E., Ravani L., Contado C., Costenaro A., Drechsler M., Rossi D., Menegatti E., Grandini A., Cortesi R. Clotrimazole nanoparticle gel for mucosal administration. Mater. Sci. Eng., C 2012.
8. Jain S., Khare P., Gulbake A., Bansal D., Jain S.K. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Delivery 2010, 17:443-451.
9. Jung S.H., Lim D.H., Jung S.H., Lee J.E., Jeong K.S., Seong H., Shin B.C. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur. J. Pharm. Sci. 2009, 37:313-320.
10. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
11. Muller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Delivery Rev. 2002, 1(54 Suppl):S131-S155.
12. Bunjes H. Structural properties of solid lipid based colloidal drug delivery systems. Curr. Opin. Colloid Interface Sci. 2011, 16:405-411.
13. Müller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Delivery Rev. 2007, 59:522-530.
14. Saupe A., Wissing S.A., Lenk A., Schmidt C., Müller R.H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Biomed. Mater. Eng. 2005, 15:393-402.
15. Silva A.C., Santos D., Ferreira D., Lopes C.M. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr. Med. Chem. 2012.
16. Rossi S., Sandri G., Caramella C.M. Buccal drug delivery: a challenge already won?. Drug Discovery Today Technol. 2005, 2:59-65.
17. Patel V.F., Liu F., Brown M.B. Advances in oral transmucosal drug delivery. J. Controlled Release 2011, 153:106-116.
18. Shojaei A.H. Buccal mucosa as a route for systemic drug delivery: a review. J. Pharm. Pharmaceut. Sci. 1998, 1:15-30.
19. Bhati R., Nagrajan R.K. A detail review on oral mucosa of drug delivery system. Int. J. Pharm. Sci. Res. 2012, 3:659-681.
20. Sohi H., Ahuja A., Ahmad F.J., Khar R.K. Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev. Ind. Pharm. 2010, 36:254-282.
21. Bernkop-Schnurch A. Mucoadhesive systems in oral drug delivery. Drug Discovery Today Technol. 2005, 2:83-87.
22. Silva A.C., Amaral M.H., González-Mira E., Santos D., Ferreira D. Solid lipid nanoparticles (SLN)-based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: preparation and characterization studies. Colloids Surf., B 2012, 93:241-248.
23. Hamidi M., Azadi A., Rafiei P. Hydrogel nanoparticles in drug delivery. Adv. Drug Delivery Rev. 2008, 60:1638-1649.
24. Chakraborty S., Shukla D., Mishra B., Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 2009, 73:1-15.
25. Kasongo K.W., Pardeike J., Muller R.H., Walker R.B. Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers. J. Pharm. Sci. 2011, 100:5185-5196.
26. Silva A.C., Gonzalez-Mira E., Garcia M.L., Egea M.A., Fonseca J., Silva R., Santos D., Souto E.B., Ferreira D. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf., B 2011, 86:158-165.
27. Ascenso A., Duarte A., Silva A., Salgado A., Marques H.C. Formulation studies on a topical gel of tretinoin-dimethyl-beta-cyclodextrin complex. J. Incl. Phenom. Macro. 2011, 69:339-343.
28. Bernstein I.L. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J. Allergy Clin. Immun. 2000, 105:39-44.
29. Finsy R., De Jaeger N. Particle sizing by photon correlation spectroscopy. Part II: Average values. Part. Part. Syst. Char. 1991, 8:187-193.
30. ISO, ISO 22412:2008, Particle Size Analysis-Dynamic Light Scattering (DLS), Switzerland, 2008.
31. Hiemenz P.C., Rajagopalan R. Principles of Colloid and Surface Chemistry 1997, Marcel Dekker, New York. third ed.
32. Swathi G., Prasanthi N.L., Manikiran S.S., Ramarao N. Solid lipid nanoparticles: colloidal carrier systems for drug delivery. Int. J. Pharm. Sci. Res. 2010, 1:1-16.
33. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol. 2010, 115-141.
34. Araujo J., Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 2010, 393:167-175.
35. Celia C., Cilurzo F., Trapasso E., Cosco D., Fresta M., Paolino D. Ethosomes® and transfersomes® containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed. Microdevices 2012, 14:119-130.
36. CLSI, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard-Second Edition., in: CLSI (Ed.) CLSI document M27-A2 Pennsylvania, USA 2002.
37. Winnicka K., Wroblewska M., Wieczorek P., Sacha P.T., Tryniszewska E. Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity. Molecules 2012, 17:4612-4624.
38. Lee C.H., Moturi V., Lee Y. Thixotropic property in pharmaceutical formulations. J. Controlled Release 2009, 136:88-98.
39. Silva A.C., Lopes C.M., Fonseca J., Soares M.E., Santos D., Souto E.B., Ferreira D. Risperidone release from solid lipid nanoparticles (SLN): validated HPLC method and modelling kinetic profile. Curr. Pharm. Anal. 2012, 8:307-316.
40. Sarkar A., Goh K.K.T., Singh H. Colloidal stability and interactions of milk-protein-stabilized emulsions in an artificial saliva. Food Hydrocolloid 2009, 23:1270-1278.
41. Siepmann J., Siepmann F. Mathematical modeling of drug delivery. Int. J. Pharm. 2008, 364:328-343.
42. Costa P., Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13:123-133.
43. Silva A.C., Santos D., Ferreira D.C., Souto E.B. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie 2009, 64:177-182.
44. Chauhan B., Shimpi S., Mahadik K.R., Paradkar A. Preparation and evaluation of floating risedronate sodium-Gelucire 43/01 formulations. Drug Dev. Ind. Pharm. 2005, 31:851-860.
45. Chauhan B., Shimpi S., Mahadik K.R., Paradkar A. Preparation and evaluation of floating risedronate sodium Gelucire® 39/01 matrices. Acta Pharm. 2004, 54:205-214.
46. Neves A.R., Lucio M., Martins S., Lima J.L., Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomed. 2013, 8:177-187.
47. Kheradmandnia S., Vasheghani-Farahani E., Nosrati M., Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed. Nanotechnol. 2010, 6:753-759.
48. Tabatt K., Sameti M., Olbrich C., Muller R.H., Lehr C.M. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm. 2004, 57:155-162.
49. Medrzycka K.B. The effect of particle concentration on zeta potential in extremely dilute solutions. Colloid Polym. Sci. 1991, 269:85-90.
50. Lage O.M., Bondoso J., Catita J.A. Determination of zeta potential in Planctomycetes and its application in heavy metals toxicity assessment. Arch. Microbiol. 2012, 194:847-855.
51. Ribeiro A., Figueiras A., Santos D., Veiga F., Preparation Solid-state characterization of inclusion complexes formed between miconazole and methyl-β-cyclodextrin. AAPS PharmSciTech 2008, 9:1102-1109.
52. Council of Europe, European Pharmacopoeia, 2010.
53. Jain S.K., Gupta A. Development of Gelucire 43/01 beads of metformin hydrochloride for floating delivery. AAPS PharmSciTech 2009, 10:1128-1136.
54. Puglia C., Frasca G., Musumeci T., Rizza L., Puglisi G., Bonina F., Chiechio S. Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. Eur. J. Pharm. Biopharm. 2012, 81:288-293.
55. Puglia C., Bonina F., Rizza L., Blasi P., Schoubben A., Perrotta R., Tarico M.S., Damiani E. Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies. J. Pharm. Sci. 2012, 101:301-311.
56. Muller R.H., Runge S.A., Ravelli V., Thunemann A.F., Mehnert W., Souto E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN (R)): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 2008, 68:535-544.
57. Üner M., Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2007, 2:289-300.
58. Liu K., Sun J., Wang Y., He Y., Gao K., He Z. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev. Ind. Pharm. 2008, 34:465-471.
59. Gokce E.H., Korkmaz E., Dellera E., Sandri G., Bonferoni M.C., Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int. J. Nanomed. 2012, 7:1841-1850.
60. ICH, Validation of analytical procedures: text and methodology Q2(R1), ICH Harmonised Tripartite Guideline, 2005.
61. Celia C., Trapasso E., Cosco D., Paolino D., Fresta M. Turbiscan lab expert analysis of the stability of ethosomes and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf., B 2009, 72:155-160.
62. Araujo J., Nikolic S., Egea M.A., Souto E.B., Garcia M.L. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf., B 2011, 88:150-157.
63. Gupta M., Vyas S.P. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem. Phys. Lipids 2012, 165:454-461.
64. Bernstein I.L. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J. Allergy. Clin. Immun. 2000, 105:39-44.
65. Wavikar P., Vavia P. Nanolipidgel for enhanced skin deposition and improved antifungal activity. AAPS PharmSciTech 2012.
66. Gonzalez-Mira E., Nikolic S., Calpena A.C., Egea M.A., Souto E.B., Garcia M.L. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J. Pharm. Sci. 2012, 101:707-725.
67. M.P. Alves, R.P. Raffin, S.B. Fagan, in: R. Beck, S. Guterres, A. Pohlmann (Eds.), Nanocosmetics and Nanomedicines: New Approaches for Skin Care, Springer, 2011 (Chapter 2).
68. Souto E.B., Muller R.H. The use of SLN (R) and NLC (R) as topical particulate carriers for imidazole antifungal agents. Pharmazie 2006, 61:431-437.
69. Mehnert W., Mader K. Solid lipid nanoparticles-production, characterization and applications. Adv. Drug Delivery Rev. 2001, 47:165-196.
70. Hoare T.R., Kohane D.S. Hydrogels in drug delivery: progress and challenges. Polymer 2008, 49:1993-2007.
71. Parashar A.K., Kakde D., Chadhar V., Devaliya R., Shrivastav V., Jain U.K. A review on solid lipid nanoparticles (SLN) for controlled and targeted delivery of medicinal agents. Curr. Res. Pharm. Sci. 2011, 02:37-47.
72. Radin S., Chen T., Ducheyne P. The controlled release of drugs from emulsified, sol gel processed silica microspheres. Biomaterials 2009, 30:850-858.
73. Kockisch S., Rees G.D., Tsibouklis J., Smart J.D. Mucoadhesive, triclosan-loaded polymer microspheres for application to the oral cavity: preparation and controlled release characteristics. Eur. J. Pharm. Biopharm. 2005, 59:207-216.
74. Silva A.C., Amaral M.H., González-Mira E., Santos D., Ferreira D. Solid lipid nanoparticles (SLN)-based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: preparation and characterization studies. Colloids Surf., B 2012.
75. Lin C.C., Metters A.T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Delivery Rev. 2006, 58:1379-1408.